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Epigallocatechin-3-Gallate Improves Acne in Humans
by Modulating Intracellular Molecular Targets and
Inhibiting P. acnes
Ji Young Yoon1,4, Hyuck Hoon Kwon1,2,4, Seong Uk Min1,2, Diane M. Thiboutot3 and Dae Hun Suh1,2
Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and
Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To
identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol
in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG
reduced sebum by modulating the AMPK–SREBP-1 signaling pathway. EGCG also reduces inflammation by
suppressing the NF-kB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and
decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most
importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well
tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.
Journal of Investigative Dermatology (2013) 133, 429–440; doi:10.1038/jid.2012.292; published online 25 October 2012
INTRODUCTION
Acne vulgaris is the most prevalent skin disorder, affecting
more than 85% of adolescents in the United States (James,
2005; Thiboutot, 2008; Williams et al., 2011). Although not
life threatening, acne can persist throughout life and leave
permanent scarring on the face, thereby causing significant
physical and psychosocial morbidities (Layton, 2001). During
the past decade, four major pathological processes have been
discovered to have a critical role in the development of acne:
(1) increased sebum production by the sebaceous gland, (2)
altered keratinization of follicular keratinocytes, (3) activity of
Propionibacterium acnes, and (4) inflammation (Leyden,
1997; Haider and Shaw, 2004; Zouboulis et al., 2005).
Despite this significant progress, most medical and surgical
modalities developed so far to treat acne have demonstrated
relatively modest efficacy, presumably because of the
inherent pathological complexity of the disease. Only a
few drugs target multiple pathological processes of acne
and effectively improve the condition, but their use is
accompanied by potentially serious side effects (Sun, 1988;
Leyden, 1997). For example, one of the most effective
treatments, isotretinoin, has serious side effects, including
teratogenicity, liver enzyme abnormalities, and dyslipidemia,
and its use is strictly limited in many countries (James, 2005;
Thiboutot, 2008). Topical retinoids, currently considered
as the first-line treatment of acne, may cause burning and
irritation, especially in the early stages of treatment (Strauss
et al., 2007). Therefore, new drugs that target multiple
pathological processes of acne with few side effects are
urgently needed.
Epigallocatechin-3-gallate (EGCG), the major polyphenol
in green tea, has attracted much interest in recent years
because of its potent anticarcinogenic, anti-inflammatory,
and antimicrobial activities (Lu et al., 2002; Tachibana et al.,
2004; Yusuf et al., 2007). Accumulating evidence indicates
that EGCG inhibits tumor progression and improves inflam-
matory diseases such as diabetes, allergies, and neurodegene-
rative disorders (Dufresne and Farnworth, 2001; Nomura
et al., 2001; Siddiqui et al., 2008; Bieschke et al., 2010). In
addition, a recent study showed that EGCG inhibits lipogen-
esis (Moon et al., 2007; Ku et al., 2009). These observations,
together with the fact that acne is closely related to abnormal
bacterial proliferation, inflammation, and lipogenesis, led us
to hypothesize that EGCG may be beneficial in acne.
In this study, we report that EGCG displays apoptotic,
sebosuppressive, and anti-inflammatory effects on human
sebocytes, and that it displays antibacterial effects on
P. acnes, findings that are, to our knowledge, previously
unreported. Our biochemical, genetic, and cellular studies
indicate that modulation of AMPK–SREBP-1 and NF-kB/
activator protein 1 (AP-1) signaling pathways mediates
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the sebosuppressive and anti-inflammatory effects of EGCG,
respectively. Subsequently, and more importantly, we con-
firmed its efficacy and safety in an 8-week randomized,
split-face, clinical trial. Taken together, these data demon-
strate that EGCG modulates several key pathological
factors of acne with very few, relatively mild side effects,
suggesting the possibility that EGCG may be effective in the
treatment of acne.
RESULTS
EGCG decreases lipogenesis in human SEB-1 sebocytes
As excessive sebum production is considered pivotal in the
pathogenesis of acne, we first examined whether EGCG can
modulate lipid production in human SEB-1 sebocytes, a well-
established in vitro model for the study of sebaceous gland
activity (Thiboutot et al., 2003). Lipogenesis was first
analyzed by total lipid assay from SEB-1 sebocytes grown
in the presence of 14C-acetate after treatment with different
concentrations of EGCG and normalized by cell numbers.
Then, changes in specific lipid components were further
analyzed using thin-layer chromatography. EGCG signifi-
cantly decreases the incorporation of 14C-acetate into total
lipids, displaying 55% decreased levels of intracellular lipids
in SEB-1 sebocytes treated with 40 mM of EGCG (Figure 1a).
This decrease mainly results from the reduction in cholesterol
and triglyceride levels (Figure 1b). Thin-layer chromatogra-
phy data on other sebaceous lipids are presented in
Supplementary Table S1 online.
To gain a mechanistic understanding of the antilipogenic
effects of EGCG, we tested the hypothesis that sterol
regulatory element–binding proteins (SREBPs), major tran-
scription factors responsible for the regulation of cholesterol/
fatty acid metabolism, are involved (Chen et al., 2004;
Engelking et al., 2004; Goldstein et al., 2006; Smith et al.,
2006, 2008). We found that EGCG significantly decreases
both precursor and mature forms of SREBP-1 proteins (Figure
1c). In addition, EGCG also decreased mRNA levels of
all SREBP isoforms, SREBP-1a, SREBP-1c, and SREBP-2, as
measured by quantitative real-time PCR, suggesting that
EGCG inhibits the expression of SREBPs at the transcriptional
level. Consistent with this result, the expression levels of two
key downstream targets of SREBPs, fatty acid synthase, and
acetyl-CoA carboxylase, were significantly decreased (Figure
1d). Together, these data suggest that EGCG suppresses
sebum, at least in part, through the inhibition of the SREBP
signaling pathway.
AMPK pathway is mainly responsible for the suppression of
lipogenesis by EGCG treatment in SEB-1 sebocytes
To identify upstream regulators responsible for the EGCG-
mediated suppression of the SREBP pathway, we have
focused on the AMP-activated protein kinase (AMPK) path-
way for the following reasons: (1) previous studies showed
that EGCG modulates the activity of AMPK in hepatocytes
and adipocytes (Hwang et al., 2005; Collins et al., 2007); (2)
AMPK is well known to act as a master regulator of lipid
metabolism in various cell lines (Zhou et al., 2001; Canto
et al., 2009; Chau et al., 2010); and (3) recent studies
described that AMPK directly phosphorylates and inhibits
SREBP activity and also regulates the transcription of SREBPs
in hepatocytes (Li et al., 2011).
We found that EGCG increases phosphorylation (Thr172)
of AMPK and acetyl-CoA carboxylase (Ser79), a well-
characterized target of AMPK, suggesting that EGCG activates
the AMPK pathway in SEB-1 sebocytes, as shown in other cell
lines (Hwang et al., 2005; Collins et al., 2007) (Figure 1e). To
test whether AMPK activation is required for the EGCG-
mediated decrease of SREBP-1, we used a selective chemical
inhibitor of AMPK, compound C (McCullough et al., 2005).
We confirmed that compound C efficiently inhibits the
EGCG-induced activation of AMPK. More importantly,
compound C blocked the reduction of SREBP-1 expression
induced by EGCG, suggesting that AMPK is a critical
mediator of EGCG’s inhibition of SREBP-1 expression (Figure
1e). Subsequently, we found that inhibition of AMPK also
reverses the sebosuppressive effects of EGCG. SEB-1 sebo-
cytes treated with EGCG showed a significant decrease in
intracellular lipid levels, as measured by Nile Red staining
(Figure 1f and g), consistent with the total lipid assay data.
However, when SEB-1 sebocytes were pretreated with
compound C, EGCG failed to decrease intracellular lipid
levels (Figure 1f and g). These data suggest that EGCG
suppresses lipogenesis in SEB-1 sebocytes via modulation of
the AMPK-SREBP-1 pathways.
EGCG decreases inflammation induced by heat-inactivated
P. acnes through the inhibition of NF-jB and AP-1 pathways
P. acnes colonization of the follicule is another critical
pathological factor for acne, which increases the inflamma-
tory response within the pilosebaceous unit (Graham et al.,
2004; Kang et al., 2005; Nagy et al., 2006). Heat-inactivated
P. acnes induced several molecular markers of inflammation,
including IL-1a, IL-1b, tumor necrosis factor (TNF)-a, and
IL-8, in SEB-1 sebocytes (Figure 2a). ELISA confirmed the
increased expression of TNF-a and IL-8, and western blot
analysis also demonstrated increased levels of the gelatinases,
matrix metalloproteinase (MMP)-2 and MMP-9 (Figure 2b
and c). To further investigate the underlying molecular
mechanisms, we checked the activation of several transcrip-
tion factors responsible for regulation of the inflammatory
response. Among them, phosphorylation of c-Jun and
phospho-IkB, a molecular marker for the activation of AP-1
and NF-kB pathway, respectively, is significantly increased
(Figure 2c). Nuclear translocation of NF-kB p65 is also
increased as expected (Figure 2d). In addition, IL-1a, a critical
cytokine involved in follicular hyperkeratosis, was induced
in HaCaT keratinocytes stimulated with heat-inactivated
P. acnes, confirming the role of skin parenchymal cells in
the pathological inflammatory response associated with acne
(Figure 2e and f).
Supporting its potential anti-inflammatory effects, EGCG
significantly decreased mRNA levels of IL-1a, IL-1b, IL-8, and
TNF-a in SEB-1 sebocytes stimulated with heat-inactivated
P. acnes (Figure 2a). Consistent with these results, protein
expression of those targets was similarly affected. Specifi-
cally, EGCG significantly decreased IL-8, TNF-a, MMP-2,
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Figure 1. Epigallocatechin-3-gallate (EGCG) decreases lipogenesis in SEB-1 sebocytes by suppressing the expression of sterol regulatory element–binding
protein (SREBP)-1 through the activation of the AMP-activated protein kinase (AMPK) pathway. (a) Lipogenesis was analyzed by total lipid assay from SEB-1
sebocytes grown in the presence of 14C-acetate after treatment with EGCG for 24 hours. (b) Changes in specific lipid components were further analyzed using
thin-layer chromatography (C: cholesterol, FOH: fatty alcohol, OA: oleic acid, TAG: triglyceride, WE: wax ester, CO: cholesterol oleate, SQ: squalene). Units
are mean±SE c.p.m/103 cells/hour. (c) Western blots for precursor and mature SREBP-1 were performed after treatment with EGCG for 24 hours. (d) RNA was
subjected to quantitative real-time PCR to determine the abundance of SREBP-1a, SREBP-1c, SREBP-2, fatty acid synthase (FAS), and acetyl-CoA carboxylase
(ACC) after treatment with EGCG for 24 hours. (e) Then, SEB-1 cells were pretreated with 20 mM of compound C for 30minutes, and/or were treated with
EGCG. Levels of phospho-/total AMPK and phospho-ACC were measured after 3 hours. Mature SREBP-1 levels were also measured after 12 hours. *Po0.05,
**Po0.01 compared with control (Student’s t-test, a–e). (f) SEB-1 cells pretreated with 20 mM of compound C for 30minutes and/or treated with EGCG for
24 hours were stained with Nile Red. Bar¼ 10mm. (g) Nile Red quantification was performed. Relative ratios compared with each control were recorded.
*Po0.05 between each EGCG-treated group and control; wPo0.05 between compound C–pretreated and –nontreated groups (Student’s t-test, g). All
experiments were repeated a minimum of five times (mean±SEM).
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MMP-9, phospho-c-Jun, and phospho-IkB (Figure 2b and c).
EGCG also inhibited the nuclear translocation of NF-kB p65
in SEB-1 cells, confirming that EGCG inhibits heat-inacti-
vated P. acnes–triggered upstream signaling of NF-kB
activation (Figure 2d and Supplementary Figure S1 online).
EGCG significantly suppressed increased levels of IL-1a, NF-
kB, and phospho-IkB in HaCaT keratinocytes (Figure 2e and f
and Supplementary Figure S1 online). Furthermore, when
SEB-1 sebocytes stimulated with heat-inactivated P. acnes
were pretreated with 20 mM of compound C, the effects of
EGCG on the levels of phospho-c-JUN, phospho-IkB, and
gelatinases were reversed, suggesting that the AMPK pathway
also has a role in the anti-inflammatory effects of EGCG
(Figure 2c). Our findings suggest that EGCG can decrease the
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Figure 2. Epigallocatechin-3-gallate (EGCG) decreases inflammation induced by SEB-1 sebocytes stimulated by heat-inactivated Propionibacterium acnes
through the inhibition of NF-jB and activator protein 1 (AP-1) pathways. (a–c) SEB-1 cells stimulated with heat-inactivated P. acnes were treated with EGCG for
24 hours. (a) RNA was isolated and subjected to quantitative real-time PCR (qRT–PCR) to determine the abundance of cytokines (IL-1a, IL-1b, tumor necrosis
factor (TNF)-a, and IL-8). (b) ELISA for TNF-a and IL-8 proteins in the supernatant of cultured cells was performed before and after treatments by EGCG for
24 hours. (c) Western blots of phospho-c-Jun, phospho IkBa, matrix metalloproteinase (MMP)-2, and MMP-9 in SEB-1 cells stimulated with heat-inactivated
P. acnes pretreated with 20mM of compound C for 30minutes and/or treated with EGCG were performed. (d) SEB-1 cells stimulated with heat-inactivated
P. acnes were incubated with EGCG for 30minutes and 24 hours, and then nuclear and cytosolic fractions were further isolated and assayed for NF-kB p65 by
western blotting, respectively. (e) Western blotting of phospho-IkBa, NF-kB p65, and IL-1a were performed in HaCaT keratinocytes stimulated with heat-
inactivated P. acnes before and after treatments with EGCG for 24 hours. (f) Then, qRT–PCR was performed to determine the abundance of IL-1a mRNA before
and after EGCG treatments. All experiments in a–e were repeated a minimum of five times. Data in (a, b, f) are mean±SEM. Student’s t-test was performed for
statistical comparisons of data presented in this figure: *Po0.05 between control and each P. acnes–stimulated group. wPo0.05 between P. acnes–stimulated,
EGCG-nontreated group, and each EGCG-treated group.
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inflammatory response in SEB-1 sebocytes and HaCaT
keratinocytes associated with P. acnes, by regulating AP-1
and NF-kB signaling pathways.
EGCG induces cytotoxicity of SEB-1 sebocytes via apoptosis
To investigate the temporal effects of EGCG on the viability of
SEB-1 sebocytes, MTT assays were performed. When treated
with EGCG, a significant reduction of cellular growth was
observed (Figure 3a). We observed a similar reduction in the
viability of HaCaT cells, yet to a lesser extent, indicating that
SEB-1 sebocytes were more sensitive to growth inhibition by
EGCG. DAPI (4’,6-diamidino-2-phenylindole) staining re-
vealed that nuclei of SEB-1 sebocytes became condensed and
fragmented after EGCG treatments, resembling apoptotic
nuclei (Figure 3b). To determine whether EGCG induces
apoptosis, SEB-1 sebocytes were treated with increasing
concentrations of EGCG, and then TUNEL staining was
performed. After 48 hours of EGCG treatment, there was an
increase in TUNEL-positive nuclei, suggesting increased
levels of apoptosis (Figure 3c and d). To precisely character-
ize the molecular mechanisms involved in EGCG-induced
apoptosis, the expression levels of proteins related to the
apoptotic pathway were examined. A statistically significant
increase in the ratio between Bax and Bcl-2, a critical marker
of the intrinsic apoptotic pathway, was observed in SEB-1
sebocytes treated with EGCG. Consistent with these, EGCG
also increases cleaved (active) caspase-3, confirming in-
creased levels of apoptosis. In addition, cyclin D1, an
important regulator of G1-/S-phase progression (Alao,
2007), is also decreased significantly, suggesting that EGCG
can also halt cell cycle progression (Figure 3e). These findings
indicate that EGCG decreases the viability of SEB-1 sebocytes
by increasing apoptosis and arresting cell cycle progression,
possibly leading to the suppression of hyperproliferation of
sebocytes in acne lesions.
EGCG inhibits the growth of P. acnes
The previous finding that EGCG exerts antimicrobial activity
against a diverse range of microorganisms (Bruggemann
et al., 2004; Yoda et al., 2004; Hauber et al., 2009), together
with the pathogenic role of P. acnes in the development of
acne, led us to hypothesize that EGCG might show an
antibacterial effect against P. acnes. To test this hypothesis,
mean colony-forming units of P. acnes cultured in different
concentrations of EGCG was compared with vehicle control
(Figure 3f). EGCG significantly decreases mean colony-
forming units in a dose-dependent manner, suggesting that
EGCG suppresses the growth of P. acnes (Figure 3g). These
results suggest that EGCG could target the abnormal
colonization of P. acnes in the development of acne.
EGCG improves acne and is well tolerated in a clinical trial
setting
To investigate the clinical efficacy and tolerability of EGCG
in the treatment of facial acne, an 8-week randomized,
double-blinded, split-face clinical trial was conducted. Of the
37 subjects enrolled, 35 (17 men and 18 women, mean age:
22.1) completed the 8-week study. Beginning at the baseline
visit, the affected areas on a randomly allocated half side of
the face of the subjects were treated with 1 or 5% EGCG
solution twice a day, whereas those of the affected the areas
on the opposite side were treated with vehicle control only
(3% ethanol). Clinical visits were scheduled at baseline, and
at 1, 2, 4, 6, and 8 weeks (Figure 4a). The revised Leeds score
that reflects both inflammatory (papules, pustules, nodules,
cysts) and noninflammatory (comedones) acne lesions was
used as a global assessment of acne severity. The mean
revised Leeds acne grading at baseline was 5.1±0.4
(mean±SD, range 2–7; O’Brien et al., 1998). Treatment with
1 and 5% EGCG significantly decreased the mean revised
Leeds score to 1.2±0.4 and 1.7±0.6, respectively, at week 8
(Figure 4b). Specifically, the mean noninflammatory and
inflammatory lesion counts significantly decreased from
the mean baseline value of 53.8±19.8 and 10.0±3.1 to
15.6±6.2 and 1.1±0.5, respectively, after 8 weeks of 1%
EGCG application, corresponding to 79 and 89% reduction
compared with the baseline (Figure 4c and d). Treatments
with 5% EGCG showed a parallel improvement in acne
lesion counts. Patients’ subjective assessments were analyzed
using a visual analogue scale (VAS) scale ranging from 0 to
10, and was set to 10 in all subjects at the baseline visit. Two
weeks after treatment, both 1 and 5% EGCG treatments
decreased VAS scores significantly. At the 8-week visit, VAS
scores were reduced to 3.5 and 4.9 in the 1 and 5% EGCG-
treated side, respectively (Figure 4e). The average global
assessment, lesion counts, and VAS data are presented in
Supplementary Table S2 online.
Furthermore, we examined the expression of several
proteins associated with acne in vivo. Skin specimens were
acquired from active acne lesions. Consistent with in vitro
results, EGCG significantly decreased the expression of IL-8,
SREBP-1, phospho-c-Jun, and NF-kB, as measured by
immunohistochemistry. TUNEL-positive nuclei were in-
creased after application of EGCG, suggesting that EGCG
treatment induces apoptosis, thereby suppressing hyperpro-
liferation of sebocytes in acne lesions (Figure 5). These
immunohistological results indicate that EGCG treatment
decreases the inflammatory response and increases apoptosis
in acne lesions in vivo.
EGCG treatment was generally well tolerated, and no
severe adverse effects were observed during the time window
of our study. Subtle adverse effects, such as erythema and
irritation, were observed in only four patients receiving 5%
EGCG (4 out of 18), which subsided spontaneously within a
few hours. No side effects were observed in patients receiving
1% EGCG. In conclusion, our clinical results strongly suggest
that EGCG is effective in both inflammatory and nonin-
flammatory acne lesions, with few, mild side effects. A
schematic of our overall results is illustrated in Figure 6.
DISCUSSION
Despite the advances in our understanding of the pathophy-
siological mechanisms underlying acne, the development of
drugs that target multiple pathological processes has been
limited. Our in vitro results demonstrated that EGCG can
directly target three out of four pathological processes in
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Inset is shown at  400 original magnification). (c) TUNEL staining was performed after 48 hours of incubation (Bar, 20 mm). Nuclei of each sample were stained
by methyl green. (d) Quantification of the percentage of TUNEL-positive stained cells after EGCG treatment at 48 hours. (e) Expression levels of Bcl-2, Bax,
capase-3, and cyclin D1 were measured after 12, 24, and 48hours of EGCG treatments, respectively. The ratio of Bax/Bcl-2 proteins was calculated to compare
the relative intensity. (f) Then, P. acnes was incubated under vehicle control and increasing concentrations of EGCG. (g) Percentile of colony numbers of
P. acnes according to increasing EGCG concentrations compared with control was described. All experiments (a–g) were repeated a minimum of five times
(mean ± SEM). Student’s t-test was performed for statistical comparisons, and P-values of o0.05 and o0.01 in comparison with the control were denoted
with * and **, respectively.
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acne, including excessive sebum production, inflammation,
and P. acnes overgrowth, and possibly indirectly target altered
keratinization (see below). Furthermore, our clinical trial
demonstrates that EGCG is effective in both inflammatory and
noninflammatory acne lesions, with few, mild side effects.
Together, these data suggest that EGCG may represent a new
therapeutic opportunity in acne vulgaris.
For many years, excessive sebum production has been
known to be one of the key factors in acne (Zouboulis et al.,
2002; Harper and Thiboutot, 2003), yet until recently there
has been no effective medication to reduce sebum produc-
tion except isotretinoin, whose detailed mechanism of action
is not fully known (Nelson et al., 2006, 2008). In our current
study, we demonstrate that EGCG has sebosuppressive effects
Baselinea
b c
d e
8-Weeks after EGCG treatment 8-Weeks after vehicle treatment
Noninflammatory lesion changesLeeds grade
Control Control
1% EGCG 1% EGCG
5% EGCG
5% EGCG
Control
1% EGCG
5% EGCG
7 80
70
60
50
40
30
20
10
0
N
on
in
fla
m
m
at
or
y 
le
sio
n
co
u
n
ts
M
ea
n 
re
vi
se
d 
Le
ed
s 
gr
a
di
ng
In
fla
m
m
at
or
y 
le
sio
n 
co
un
ts
6
5
4
3
2
1
1 2 4
Week
Control VAS
VA
S
12
10
8
6
4
2
0
0 1 2 4
WeekWeek
6 8
1% EGCG
5% EGCG
14
12
10
8
6
4
2
0
0 1 2 4 6 8
Inflammatory lesion changes
6 8
0
0 1 2 4
Week
6 80
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
Figure 4. Topical application of 1 and 5% epigallocatechin-3-gallate (EGCG) significantly improves acne lesions in an 8-week human clinical study. (a) A total
of 35 patients were instructed to apply EGCG solution only to one side of the face, and vehicle containing 3% ethanol to the other side. The applied side was
randomly selected for each patient. Seventeen subjects were designated to use 1% EGCG and 18 subjects were designated to use 5% EGCG to evaluate a
dose–response relationship. (b) Revised Leeds grading and acne lesion counts were performed. Changes in both (c) noninflammatory lesions (whiteheads and
blackheads, comedones) and (d) inflammatory lesions (papules, pustules, and nodules) during EGCG application period were calculated. (e) VAS was also
measured, to assess the subjective assessment of patients with time. Statistical significance was determined by Wilcoxon signed rank test: *Po0.05 between
each EGCG-treated group and baseline. wPo0.05 between each EGCG-treated group and control (Wilcoxon signed rank test). VAS, visual analogue scale.
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mainly through the regulation of AMPK-SREBP-1 signaling
pathways. EGCG activates AMPK in SEB-1 sebocytes, which
in turn decreases the expression of SREBPs and lipogenesis.
Whether the EGCG-induced downregulation of SREBPs
results solely from the direct action of AMPK on SREBPs
remains to be determined. It should be noted that EGCG
additionally inhibits the IGF-1/PI3K/Akt pathway (Supple-
mentary Figure S2 online) in an AMPK-dependent manner.
These findings, together with the fact that IGF-1/PI3K/Akt
pathway regulates lipogenesis through SREBPs (Smith et al.,
2006, 2008), suggest the possibility that AMPK may regulate
SREBPs through the IGF-1/PI3K/Akt pathway. Taken together,
our data indicate that AMPK has a critical role in the EGCG-
induced sebosuppression in SEB-1 sebocytes, offering ther-
apeutic strategies to target lipogenesis in acne.
Many human diseases are often associated with a chronic
inflammatory response, which also has a critical role in the
development of acne (Webster, 1995; Harper and Thiboutot,
2003; Yamasaki et al., 2007). We found that EGCG suppresses
the inflammatory response induced by heat-inactivated
P. acnes in SEB-1 sebocytes, a well-established in vitro model
of inflammatory acne, through the inhibition of NF-kB and
AP-1 pathways. Although the mechanism by which EGCG
regulates NF-kB and AP-1 pathways remains elusive, we
hypothesize that it acts upstream of IkB degradation, based on
our results showing that EGCG decreases phosphorylation of
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Figure 5. Histopathological changes after applying epigallocatechin-3-gallate (EGCG) for 8 weeks. IL-8, phospho-c-JUN, SREBP-1, and NF-kB p65 were
identified by staining with specific antibodies at baseline and final visits. TUNEL assay was also performed as listed in the Materials and Methods section. All are
at the same magnification (bar¼ 100 mm), and all experiments were repeated a minimum of five times (mean±SEM). Quantitative analysis was performed for
each sample. Wilcoxon signed rank test was performed, and *P-valueo0.05 was considered statistically significant compared with baseline.
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IkB. It is noteworthy that inhibition of AMPK rescued the
EGCG-induced suppression of NF-kB and AP-1 pathways,
suggesting that EGCG-activated AMPK suppresses the activity
of the NF-kB and AP-1 pathways. Consistent with these
observations, an increasing body of evidence demonstrates
that AMPK inhibits the NF-kB pathway as well as the
inflammatory response in the different types of cells (Navar-
ro-Peran et al., 2008; Green et al., 2011; Morizane et al.,
2011). It is also remarkable that EGCG decreases IL-1a in
HaCaT keratinocytes, based on the fact that IL-1a induces
hypercornification of the infundibulum in a manner similar to
that seen in comedones (Guy et al., 1996). These results
suggest that EGCG might reverse the altered keratinization of
follicular keratinocytes through the regulation of IL-1a.
Together, these data provide insight to the molecular basis
of the therapeutic effects of EGCG on the inflammatory acne
lesions in our clinical trial.
As apoptosis and cell cycle arrest can lead to drastic
decreases in sebaceous glands’ size and lipid contents, we
examined whether EGCG has an antiproliferative effect.
Indeed, we found that EGCG increases the levels of apoptosis
and cell cycle arrest. The molecular mechanisms by which
EGCG induces apoptosis and cell cycle arrest remain elusive,
yet it is plausible to assume that inhibition of either NF-kB or
Akt, or both, by EGCG causes apoptosis and cell cycle arrest,
based on the fact that the NF-kB and Akt pathways are well
recognized as prosurvival signals (Beg and Baltimore, 1996;
Chen et al., 1998). In addition, it is possible that EGCG-
activated AMPK may induce apoptosis or cell cycle arrest, as
described in recent studies (Motoshima et al., 2006; Hwang
et al., 2007). Further studies are needed to address this
question. Our findings suggest that EGCG may promote
apoptosis and cell cycle arrest in sebocytes, contributing to
decreased sebaceous glands, and therefore mitigated acne
lesions, similar to isotretinoin.
P. acnes, a Gram-positive anaerobic bacterium, is a
commensal of human skin, and its overgrowth is closely
implicated in the progression of inflammation in acne (Kim,
2005; Michalak-Stoma et al., 2008). Until recently, various
antibiotics have been used to control the overgrowth of
P. acnes, yet increasing antibiotic resistance (Strauss et al.,
2007; Thiboutot, 2008) and biofilm formation (Burkhart and
Burkhart, 2007) lead to a poor outcome. An accumulating
body of evidence suggests that EGCG shows antimicrobial
activity against a diverse range of microorganisms, including
bacteria, viruses, and fungi (Alexis et al., 1999; Dufresne
and Farnworth, 2001; Yoda et al., 2004). Indeed, we
found that EGCG significantly inhibits the growth of
P. acnes. As a possible mechanism, sophisticated molecular
interactions between triphenols of EGCG and a peptide
structure of bacterial proteins, including peptidoglycan,
was suggested, because neither amino acid, alone or in
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Figure 6. Possible therapeutic mechanisms based on our in vitro results. These mechanisms could elucidate the efficacy of epigallocatechin-3-gallate (EGCG)
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combination, showed any effect on the antibiotic effect of
EGCG (Yoda et al., 2004). This antibiotic effect of EGCG may
provide an advantage as a therapeutic strategy for the
treatment of acne, especially considering increasing concerns
about antibiotic-resistant bacteria.
Following the promising results of our in vitro studies, a
clinical trial in acne patients was conducted to examine
the therapeutic potential of EGCG on acne. Our clinical
trial revealed that 1 and 5% EGCG treatment significantly
improves both inflammatory and noninflammatory acne
lesions. Remarkably, the efficacies of EGCG in this small
study were better than those of a new compound product
reported in recent large-scale clinical trials (Thiboutot
et al., 2007; Gollnick et al., 2009). Furthermore, the rate of
overall side effects observed in our clinical trial is less
than that of the aforementioned studies. As the follicular
pathway, in contrast to the conventional transdermal
pathway, is especially favorable for the delivery of small
molecules (Mitragotri, 2003), topically administered EGCG
might be especially effective on acne lesions connected to
hair follicles.
In summary, our data demonstrate that EGCG can
modulate several key pathological factors of acne, including
hyperseborrhea, inflammation, and P. acnes overgrowth,
with few, mild side effects, suggesting that EGCG may be
used for the effective and rapid treatment of both inflamma-
tory and noninflammatory acne.
MATERIALS AND METHODS
Cell culture
The SEB-1-immortalized human sebocyte cell line was generated by
transfection of secondary sebocytes with SV40 large T antigen, as
previously described (Thiboutot et al., 2003). SEB-1 cells were
cultured and maintained in standard culture medium containing
DMEM (Invitrogen, Carlsbad, CA), 5.5mM glucose/Ham’s F-12 3:1
(Invitrogen), fetal bovine serum 2.5% (HyClone, Logan, UT), adenine
1.8 104 M (Sigma, St Louis, MO), hydrocortisone 0.4mgml1
(Sigma), insulin 10ngml1 (Sigma), epidermal growth factor
3 ngml1 (Austral Biologicals, San Ramon, CA), and cholera toxin
1.2 1010 M (Sigma) at 37 1C in a 5% CO2 incubator. The human
keratinocyte cell line HaCaT was maintained in DMEM (Invitrogen)
supplemented with 5% fetal bovine serum, 20mM L-glutamine, 1mM
sodium pyruvate, and antibiotic/antimycotic solution (10Uml1
penicillin, 10mgml1 streptomycin, and 0.25mgml1 amphoterin;
Invitrogen) at 37 1C in a 5% CO2 incubator.
Western blot analysis
Protein was extracted using cell lysis buffer (Cell Signaling
Technology, Beverly, MA). Protein contents in lysates were
determined using the BCA Protein Assay (Pierce, Rockford, IL).
Equal amounts of protein were run on 10% SDS-PAGE gels and then
transferred to a polyvinylidene difluoride membrane. The blots were
primarily probed with cleaved caspase-3 (Asp175) (5A1) rabbit
antibody, cyclin D1 (DCS6) mouse antibody, Bax rabbit antibody,
BCL-2 mouse antibody, Akt rabbit antibody, Phospho-Akt (Thr308)
rabbit antibody, Phospho-PI3K p85(Tyr 458)/p55 (Tyr199) rabbit
antibody, Phospho-IRS-1 (Ser307) rabbit antibody, Phospho-ACC
(Ser79) rabbit antibody, Phospho-AMPKa (Thr172) rabbit antibody,
AMPKa rabbit antibody, Phospho-c-Jun (Ser63) rabbit antibody,
Phospho-IkB (Ser32/36) mouse antibody (Cell Signaling Technol-
ogy), b-actin mouse antibody, Lamin A, NF-kB p65 mouse
antibody, SREBP-1 rabbit antibody (Santa Cruz Biotechnology,
Santa Cruz, CA), Phospho-IGF 1 receptor rabbit antibody (Abcam,
Cambridge, UK), MMP-2 mouse antibody, MMP-9 mouse antibody,
and IL-1a mouse antibody (R&D Systems, Minneapolis, MN).
Secondary anti-rabbit IgG and anti-mouse IgG antibody (Cell
Signaling Technology) were used to detect primary antibodies. Blots
were developed with WESTSAVE Up (LabFrontier, Seoul, South
Korea) and exposed to the film. Films of blots were analyzed and
quantified using a densitometric program (TINA; Raytest Isotopen-
mebgerate, Straubenhardt, Germany).
Thin-layer chromatography
SEB-1 cells were grown to 80% confluence in 35-mm dishes and
treated with control or different concentrations of EGCG for
24 hours. In all experiments, cells were counted to normalize the
data. The remaining cells were suspended in a DMEM solution
containing 1 mCi 14C-acetate and incubated for 2 hours at 37 1C with
agitation, and extracted twice with ethyl ether and nonradioactive
carrier lipids. Samples were dissolved in a small volume of ethyl
acetate and spotted on 20-cm silica gel thin-layer chromatography
plates (Merck, Darmstadt, Germany), which were run until the
solvent front reached 19.5 cm in hexane, followed by 19.5 cm in
benzene, and finally to 11 cm in hexane:ethyl ether:glacial acetic
acid (69.5:30:1.5). Lipid spots were visualized, excised, and radio-
activity in each spot was quantified in a liquid scintillation counter.
Each experiment was conducted at least five separate times.
This clinical study was performed in accordance with the
Declaration of Helsinki (2000) and was approved by the Institutional
Review Board of Seoul National University Hospital. Written
informed consent was obtained from each participant before study
enrollment. The study was registered with ClinicalTrials.gov under
registration ID# NCT01687556; the CONSORT participant flowchart
is provided as Supplementary Figure S3 online.
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